Evolus (EOLS) Cash from Operations Growth (1y) (2018 - 2026)
Evolus (EOLS) Cash from Operations Growth (1y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 61.90% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -22.14% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 8.20% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 0.46% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | -27.49% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 125.00% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 425.00% |
| 10 | Evolus | 403.51 Mn | 353.71 Mn | 48.90 Mn | 36.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 36.34% |
| Dec 31, 2025 | 166.78% |
| Sep 30, 2025 | -156.36% |
| Jun 30, 2025 | -283.17% |
| Mar 31, 2025 | -47.26% |
| Dec 31, 2024 | 491.39% |
| Sep 30, 2024 | -519.26% |
| Jun 30, 2024 | 51.39% |
| Mar 31, 2024 | 48.44% |
| Dec 31, 2023 | 109.27% |
| Sep 30, 2023 | 94.58% |
| Jun 30, 2023 | 36.28% |
| Mar 31, 2023 | 46.11% |
| Dec 31, 2022 | 2.99% |
| Sep 30, 2022 | 46.92% |
| Jun 30, 2022 | -229.61% |
| Mar 31, 2022 | -358.30% |
| Dec 31, 2021 | -299.12% |
| Sep 30, 2021 | -134.27% |
| Jun 30, 2021 | 215.57% |